$Moderna, Inc.(MRNA)$ $Moderna

Like
Comment
Favorite

$Moderna, Inc.(MRNA)$ $Moderna, Inc.(MRNA)$ $Merck(MRK)$ Morgan Stanley's ESMO takeaways go beyond just a positive melanoma trial. The independent discussant compared INT's RFS hazard ratio with adjuvant Herceptin's. Some physicians expressed confidence that the recurrence benefit would translate into longer overall survival. A KOL argued the effect was too large to be explained solely by general immune stimulation. Manufacturing turnaround is reportedly down to 30–40 days. RCC and bladder Phase 2 trials could have registrational potential, depending on results. More than a melanoma story: growing scientific confidence in a broader oncology platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":622328776450736,"tweetId":"622328776450736","gmtCreate":1792966616000,"gmtModify":1793007292004,"author":{"id":10000000000010952,"idStr":"10000000000010952","authorId":10000000000010952,"authorIdStr":"10000000000010952","name":"Boyd Wild","avatar":"https://static.tigerbbs.com/cc94732a0a7ba0077246f1b24ce08047","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$&nbsp;</a>Morgan Stanley's ESMO takeaways go beyond just a positive melanoma trial. The independent discussant compared INT's RFS hazard ratio with adjuvant Herceptin's. Some physicians expressed confidence that the recurrence benefit would translate into longer overall survival. A KOL argued the effect was too large to be explained solely by general immune stimulation. Manufacturing turnaround is reportedly down to 30–40 days. RCC and bladder Phase 2 trials could have registrational potential, depending on results. More than a melanoma story: growing scientific confidence in a broader oncology platform.</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$&nbsp;</a>Morgan Stanley's ESMO takeaways go beyond just a positive melanoma trial. The independent discussant compared INT's RFS hazard ratio with adjuvant Herceptin's. Some physicians expressed confidence that the recurrence benefit would translate into longer overall survival. A KOL argued the effect was too large to be explained solely by general immune stimulation. Manufacturing turnaround is reportedly down to 30–40 days. RCC and bladder Phase 2 trials could have registrational potential, depending on results. More than a melanoma story: growing scientific confidence in a broader oncology platform.</p></body></html>","text":"$Moderna, Inc.(MRNA)$ $Moderna, Inc.(MRNA)$ $Merck(MRK)$ Morgan Stanley's ESMO takeaways go beyond just a positive melanoma trial. The independent discussant compared INT's RFS hazard ratio with adjuvant Herceptin's. Some physicians expressed confidence that the recurrence benefit would translate into longer overall survival. A KOL argued the effect was too large to be explained solely by general immune stimulation. Manufacturing turnaround is reportedly down to 30–40 days. RCC and bladder Phase 2 trials could have registrational potential, depending on results. More than a melanoma story: growing scientific confidence in a broader oncology platform.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/622328776450736","repostId":0,"isVote":1,"tweetType":1,"viewCount":197,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRK","MRNA"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":568,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}